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Abstract
Although radical surgery remains the mainstay therapeutic modality for early-stage non–small-cell lung can-
cer (NSCLC), long-term survival of patients with completely resected NSCLC tumors remains suboptimal.
Globally, the 5-year survival rate of patients who undergo complete surgical resection is in the range of 40%-
50%. The majority of postsurgical relapses are represented by distant metastases, with the risk of a local
recurrence being < 10%. Postoperative treatments, including chemotherapy, radiation therapy, or both, have
been widely evaluated during recent decades. After almost 2 decades of disappointing results, the positive
outcomes of 3 randomized studies have recently generated new hopes for a significant impact on survival
by adjuvant chemotherapy. The 2 largest randomized studies of adjuvant chemotherapy in all stages (I-IIIA)
of completely resected NSCLC that were adequately powered to detect small differences in survival yielded
partially conflicting results but indicated that, if any benefit from adjuvant chemotherapy exists, it is ap-
proximately 5% at 5 years, as previously anticipated by a metaanalysis. More recently, 2 other randomized
studies in selected subgroups of patients (one selectively performed in stage IB disease, the other in stage
IB/II disease) indicate an unexpected significant benefit of approximately 15% at 5 years. Potential con-
founding factors may have contributed to such a significant benefit. A feature common to all these trials is
the suboptimal therapeutic compliance to adjuvant chemotherapy, suggesting the need for careful selection
of patients to be considered for adjuvant treatment. Genomic- and proteomic-driven chemotherapy as well
as molecularly targeted therapies may represent additional areas of near-future clinical investigations. 
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Introduction
Surgery represents the main curative therapeutic approach for
early-stage disease (stages IA-IIB) non–small-cell lung cancer
(NSCLC). Unfortunately, these cases represent only a minority
(20%-25%) of cases of NSCLC. Specific groups of patients with
stage III disease also benefit from pulmonary resection, usually
in combination with other treatment modalities. The use of a
systemic therapy in completely resected NSCLC is reasonably
justified by follow-up studies after radical resection that have
shown predominance of distant failures over local recurrences
and some clinical and pathologic evidence of early microdis-
semination of disease at the time of surgery.
Pattern of Relapse After Complete 
Resection for Early-Stage NSCLC
Long-term survival in NSCLC following surgical resection is
stage-related, but even in stage IA, one third of patients will relapse
and die of disease within 5 years.1 The majority of these relapses
are distant metastases, with the risk of a local recurrence after com-
plete resection being < 10%. The brain is the most common site
of metastatic recurrence, followed closely by bone, ipsilateral and
contralateral lung, liver, and adrenals. More than 80% of recur-
rences occur within 2 years from the time of radical surgery.2
The rate of recurrence for patients with stage II disease is high-
er than in stage I; > 50% of resected stage II disease can be ex-
pected to relapse and most recurrences are distant. The pattern
of recurrence may differ by histology with more local recurrences
seen for patients with squamous cell carcinoma and more distant
metastases seen in patients with adenocarcinoma.3-6
The Rationale for Adjuvant Treatments 
Following complete resection, tumor load, if any, is theoreti-
cally minimal. The relatively small number of residual neoplas-
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tic cells present in micrometastatic disease should contain few
chemotherapy- or radiation-resistant clones. The Gompertzian
model of tumor growth and regression fits experimental and
clinical data of most human solid cancers—if the assumptions
are effectively correct, when the tumor is clinically undetectable,
its growth rate should be at its largest, and, although the nu-
meric reduction induced by cytotoxic chemotherapy is small,
the fractional cell kill from an effective dose of chemotherapy
should be higher.7 In addition, pathologic staging allows better
prediction of prognosis and facilitates the comparison of treat-
ment results between different trials. 
Adjuvant Radiation Therapy
For a long period of time, postoperative thoracic radiation
therapy (RT) was the preferred adjuvant treatment. Results re-
garding its potential role have been reported from a large num-
ber of retrospective and prospective studies. Nine of these
studies, collecting individual data from 2128 patients, have
been included in the postoperative RT (PORT) metaanalysis
and indicated PORT as a treatment with significant detrimen-
tal effect on survival. Data indicated a 21% relative increase in
the risk of death, equivalent to an absolute detriment of 7% at
2 years, reducing the survival rate from 55% to 48% with
PORT (P = 0.001; hazard ratio [HR], 1.21; 95 CI, 1.08-1.34).
Subset analyses suggested a trend toward greater negative effects
for lower nodal status (P = 0.016 for nodal status 0-2) and ear-
lier stages of disease (P = 0.0003 for stage I-III), with a distinct
survival detriment for stage I disease and a clear lack of benefit
or detriment for stage III disease.8
Most of the studies included in the PORT metaanalysis in-
corporated patients treated with older technology (cobalt 60)
and different dosimetry, and these outdated parameters may be
partially responsible for the higher mortality rate observed in the
RT group attributable to an excess of intercurrent deaths. The
use of newer technologies and improved dosimetry may prove to
be effective, as more recently suggested in a retrospective re-
view.9 In addition, in the PORT metaanalysis, there were no
sufficient data on mediastinal lymph node dissection and the
surgical procedure varied greatly among studies and centers.
Consequently, the role of RT in patients with N2 disease re-
mains unclear, as no definitive conclusions can be drawn from
the PORT metaanalysis. 
A study not included in the metaanalysis was subsequently re-
ported and aimed to investigate the value of adjuvant postoperative
external-beam RT in patients with radically resected NSCLC (pT1-
3 pN0-2) compared with patients with resected NSCLC without
adjuvant external-beam irradiation. In that study, 155 patients were
randomized to surgery alone (n = 72) or surgery followed by PORT
(n = 83). With a median follow-up of 3.6 years, there was no sta-
tistically significant difference in the overall 5-year survival rate
(20.4% with surgery alone vs. 29.7% with surgery plus PORT;
P > 0.05). A subgroup analysis conducted separately for each
pathologic stage did not result in any significant survival benefit for
PORT when compared with surgery alone at 5 years (pN0 and
pN1) or 2 years (pN2).10 New randomized studies are awaited to
assess the impact of adjuvant RT on local control and survival.
However, in consideration of the pattern of recurrence and re-
lapse observed in patients who had previously completely resect-
ed early-stage NSCLC, it is quite unlikely that a local treatment
such as postoperative RT—although it may potentially improve
local control rate—will be able to significantly modify the sur-
vival of patients who have surgically resected early-stage NSCLC.
Only the use of an effective systemic treatment that will eradicate
micrometastatic clones has the potential to significantly affect
survival. Theoretically, the combination of thoracic RT, delivered
through the latest-generation RT machines, and platinum-based
combination chemotherapy allows the optimization of local con-
trol and extrathoracic micrometastatic disease. 
History of Adjuvant Chemotherapy
in Early-Stage NSCLC
The history of adjuvant chemotherapy in completely resected
NSCLC began in the early 1960s and 1970s with trials testing
the roles of alkylating agents and nonspecific immunotherapies
(mainly levamisole and Bacillus Calmette-Guérin) that uniform-
ly failed to demonstrate any survival benefit; occasionally, a detri-
mental effect was observed.11 All the drugs used in these studies
had shown very limited or no activity in advanced NSCLC.
How does one select the most appropriate treatment to be
used in the adjuvant setting? Realistically, no definitive rules
have been established, but the chosen treatment should at least
be proven active in advanced-stage disease and be associated
with good tolerability.12
In the 1980s, the role of cisplatin-based combinations was ex-
tensively tested. These studies may be grouped into 2 series.
Most of these studies included patients with predominantly
stage III NSCLC, and CAP (cyclophosphamide/ doxorubicin/cis-
platin) was more commonly investigated. All these studies failed
to show any improvement in median and long-term survival.13-17
Two other studies testing the role of cisplatin-based
chemotherapy were performed, mostly in patients with stage I
disease.18,19 In one of these studies, 110 patients with complete-
ly resected T1 3N0 NSCLC were randomized to receive CAP or
no additional therapy. After 10 years of follow-up, survival was
significantly better in the experimental arm than in the control
arm (61% vs. 48%, P = 0.05).18 In the second study, eligible pa-
tients with completely resected stage I NSCLC were classified by
known prognostic factors and randomly assigned to receive 4
courses of CAP at 3-week intervals beginning on day 30 after
surgery or no treatment. The CAP regimen consisted of 400
mg/m2 cyclophosphamide, 40 mg/m2 doxorubicin, and 60
mg/m2 cisplatin. Stratification by prognostic factors included
histology, white blood cell count before surgery, and Karnofsky
performance status before surgery. After a mean follow-up of 3.8
years, there were no differences in time to recurrence or overall
survival (OS; not stratified by histology) between the 2 groups,
even when analyses were adjusted for prognostic variables.19
Findings among these studies include variation in sample size,
overestimation of the potential benefit of adjuvant chemothera-
py, imbalance in patient and treatment characteristics (ie, in-
complete mediastinal lymph node dissection), and, for a
majority of these studies, impossibility of reaching the planned
Adjuvant Chemotherapy in NSCLC
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accrual. These flaws possibly reflect negative attitudes of tho-
racic surgeons toward adjuvant chemotherapy, and the modern
multidisciplinary approach to patients with early-stage NSCLC
may be a way to overcome this problem. 
In addition, most of the trials’ dose delivery, including total
dose and dose intensity of chemotherapy agents, was often re-
ported to be inadequate, with an average of 50% of patients re-
ceiving the full course of treatment.
Recent Studies of Adjuvant Chemotherapy in NSCLC
In 1995, a metaanalysis performed with different subgroups
of patients with NSCLC receiving chemotherapy analyzed 8 cis-
platin-based adjuvant chemotherapy trials in 1394 patients and
demonstrated a 13% reduction of the risk of death, which was
close to the borderline of statistical significance (P = 0.08).
Similarly, there was a 6% reduction in the risk of death in pa-
tients treated with PORT and cisplatin-based chemotherapy
compared with patients who received only PORT (P = 0.46).
Conversely, adjuvant chemotherapy with long-term alkylating
agents was significantly detrimental.20
These findings failed to affect clinical practice, not because
the absolute gain was too small, but because such an estimate
was still imprecise, ranging from a 1% detriment to a 10% ben-
efit. In addition, the heterogeneity of surgical procedures and
the difference in staging modalities strongly limit the applica-
bility of the results of this metaanalysis. This was not the case,
for example, for breast cancer adjuvant chemotherapy, the sim-
ilarly narrow 6% benefit of which in 10-year survival rate
emerged from a metaanalysis involving approximately 75,000
patients, with 31,000 recurrences and 24,000 deaths.21
This statistically insignificant benefit in 5-year survival of the
previously mentioned NSCLC metaanalysis generated enough
enthusiasm to prompt the planning of several randomized stud-
ies, all platinum agent–based (with or without thoracic RT) in
completely resected NSCLC of stages I-IIIA (Table 1).22-26
The first study published was an Eastern Cooperative Oncol-
ogy Group (ECOG) trial in which patients with clinical stage
II/IIIA NSCLC after complete resection received RT alone or
concurrent chemotherapy/RT. Overall toxicity was higher in the
chemotherapy/RT group, but no difference was seen in efficacy
outcomes.27 This study was criticized for the small sample size
and for the absence of a pure control arm.
The studies in Table 1 are worthy of initial considerations.
First, among these studies there is a huge difference in the sam-
ple size calculation, from < 500 patients to > 3000, to observe the
same therapeutic effect in the same patient population. Second,
some of these studies tested the role of adjuvant chemotherapy in
all stages of resected NSCLC, whereas others addressed the same
question to specific and well-defined subgroups of patients.
Third, the only 2 trials designed to observe a reasonable survival
advantage in the range of that previously described in the meta-
analysis were the Adjuvant Lung Project Italy (ALPI) study and
the International Adjuvant Lung Trial (IALT).22,23
The ALPI trial, conducted in 70 Italian centers and 7 Euro-
pean institutions affiliated with the European Organization
for Research and Treatment of Cancer (EORTC), randomized
patients surgically staged with stages I, II, and IIIA NSCLC to
receive MVP (mitomycin 8 mg/m2 on day 1, vindesine 3
mg/m2 on days 1 and 8, and cisplatin 100 mg/m2 on day 1
every 3 weeks for 3 cycles) or no chemotherapy.23 Delivery of
PORT (total dose 50-54 Gy in 5-6 weeks, beginning ≥ 4
weeks after the completion of chemotherapy) was left to the
policy of participating centers and randomization was strati-
fied accordingly (Table 2).22,23
Between January 1994 and February 1998, 1209 patients were
randomized. After a median follow-up of 64.5 months, differ-
ences in progression-free survival (PFS; HR, 0.89; P = 0.144)
and OS (HR 0.96; P = 0.585) were not statistically significant.
Only 69% of patients received the 3 full MVP cycles with or
without dose adjustments or omissions. On multivariate analy-
sis, only stage and sex emerged as independent prognostic fac-
tors. Moreover, there was no good evidence of differential
effect of chemotherapy in the different subgroups of patients;
in stage I, II, and IIIA disease, the HRs for survival were 0.97
(95% CI, 0.71-1.33), 0.80 (95% CI, 0.60-1.06) and 1.06
(95% CI, 0.82-1.38), respectively (for interaction, P = 0.52).
Similar figures were found for PFS: HRs of 0.89 (95% CI,
0.66-1.19), 0.78 (95% CI, 0.60-1.03), and 0.94 (95% CI,
0.73-1.21), respectively. It is remarkable to observe that, in the
subgroup of patients with stage II NSCLC, although the HR
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ANITA I
Intergroup 0116
JCOG
IALT22*
ALPI23*
BLT24*
CALGB 963325
NCIC BR.1026
International
United States
Japan
International
Italy/Europe
United Kingdom
United States
Canada
I, II, IIIA
T1-3 N1/2 
IIIA N2
I, II, IIIA
I, II, IIIA
I, II, IIIA
IB
T2 N0 T1/2 N1
Study Site
Observation
RT
Observation
Observation
Observation
Observation
Observation
Observation
Control
Arm
800
462
200
3300
1200
481
504
640
Planned
Accrual
831
488
119
1867
1209
381
344
482
Actual
Accrual
Pending
Negative
Negative
Positive
Negative
Negative
Positive
Positive
Trial 
Outcome 
     
Disease
Stage
Cisplatin/Vinorelbine for 4 cycles
Cisplatin/Etoposide for 4 cycles
Cisplatin/Vindesine
Cisplatin/Etoposide or Vinca Alkaloids for 3-4 cycles
Cisplatin/Mitomycin C/Vindesine for 3 cycles
Cisplatin/Etoposide or Vinca Alkaloids for 3 cycles
Carboplatin/Paclitaxel for 4 cycles
Cisplatin/Vinorelbine for 4 cycles
Chemotherapy Regimen
Recent Randomized Clinical Studies of Platinum Agent–Based Adjuvant Chemotherapy in Completely Resected NSCLC22-26Table 1
*Sequential thoracic RT allowed according to each institution policy; 13% received RT in both arms of the study. 
Abbreviations: ANITA = Adjuvant Navelbine International Trialist Association; BLT = Big Lung Trial; JCOG = Japanese Clinical Oncology Group
S66 Clinical Lung Cancer Vol 6 • Suppl 2 December 2004
was not statistically significant, a 10% survival advantage at 5
years for chemotherapy-treated patients was reported.23
In this trial, the choice for a triplet combination was suggest-
ed by the positive data reported from a trial comparing 3
chemotherapy regimens in patients with advanced NSCLC28
and by the efficacy of the MVP regimen in the neoadjuvant set-
ting.29 In patients with stage IIIA NSCLC, triplet combinations
were used as induction regimens in 2 small randomized phase
III trials that showed a clinically meaningful superiority of the
combined approach over surgery alone.30,31
The other large worldwide randomized trial, the IALT trial,
was aimed at determining the impact on OS of a chemothera-
py regimen including cisplatin (80-120 mg/m2) and a vinca al-
kaloid (vindesine 3 mg/m2 weekly, vinblastine 4 mg/m2 weekly,
or vinorelbine 30 mg/m2 weekly) or etoposide (100 mg/m2
daily for 3 consecutive days) compared with no chemotherapy
after complete surgical resection in patients with stage I-III
NSCLC22 (Table 2).22,23 Chemotherapy treatment was admin-
istered every 3-4 weeks. As in the ALPI trial, thoracic RT could
be given according to the preregistration policy of each center.
The planned number of patients was 3300 to observe a 5% sur-
vival difference at 5 years (from 50% to 55%). The study start-
ed in 1995 and was stopped in December 2000 because of slow
accrual after enrolling 1867 patients. The median follow-up
was 56 months. Compliance with chemotherapy was good;
74% of patients received ≥ 240 mg/m2 of cisplatin. Only 23%
of patients on the chemotherapy arm experienced grade 4 tox-
icity. There was a toxic death rate of 0.8%, which was attrib-
uted to the administration of chemotherapy. Disease-free
survival and OS were increased by chemotherapy, with absolute
survival benefits of 5.1% (P = 0.003) and 4.1% (P = 0.03), re-
spectively.22 However, a comparison of the risk–benefit profile
of the different regimens used in this study is clearly difficult to
ascertain, as the choice of regimen
was not stratified and patient case
mix among centers could be ex-
tremely variable.
In the ALPI and IALT studies, re-
lapse and recurrence of neoplastic
disease accounted for the main cause
of death and, more relevantly, in
both arms of the ALPI study, > 40%
of patients had brain relapses. 
Another feature common to both
trials was the suboptimal compli-
ance with adjuvant chemotherapy,
with 8% and 9% of patients who
never received chemotherapy and
26%-31% of patients who received
less than the 3 planned courses of
treatment, which compromised the
relative dose intensity. In a compar-
ative analysis of IALT and ALPI,
delivery ability of chemotherapy
did not differ dramatically when a
doublet combination was used in-
stead of a triplet combination. Furthermore, the ALPI study
showed that MVP conferred only a small, statistically non-
significant, OS advantage even in the per-protocol exploratory
analysis that compared outcomes among patients receiving all
3 planned cycles of chemotherapy with those of patients un-
dergoing no adjuvant therapy. 
Reasons for reduced therapeutic compliance may be related to
the need for more time to fully recover from the surgical proce-
dure itself for patients with lung cancer in comparison with the
time needed for patients with breast cancer and may also be re-
lated to a negative selection bias of the patients enrolled in both
studies. In the ALPI and IALT studies, 26% and 35% of pa-
tients received pneumonectomies, a percentage far exceeding
the normal pneumonectomy rate in any surgical series.
Data have been recently reported about adjuvant chemother-
apy in a subgroup of patients with surgically resected disease
enrolled in the British Big Lung Trial. Three hundred sixty-
eight patients were randomized to receive cisplatin-based dou-
blet (38%) or triplet regimens (62%). The reported HR for OS
was 1.02, but the limited sample size, quality of surgery, and
limited follow-up period greatly reduce the power of the infor-
mation provided.29
Different from ALPI and IALT, 2 additional adjuvant trials
used third-generation chemotherapy regimens and were focused
on a more restricted patient population. The results of the 2 tri-
als were presented at the 40th Annual Meeting of the American
Society of Clinical Oncology in 2004. Both studies were de-
signed in the mid-1990s to compare adjuvant carboplatin/pacli-
taxel (Cancer and Leukemia Group B [CALGB] 9633 study)25
or cisplatin/vinorelbine (National Cancer Institute of Canada
[NCIC] BR.10 study)26 with no adjuvant therapy for patients
with completely resected stage IB disease (CALGB trial) or stage
IB/II NSCLC (NCIC-BR.10; Table 3).25,26
Adjuvant Chemotherapy in NSCLC
Median Age
Pathologic Stage
 I
 II
 IIIA
Histology
   Squamous cell
   Non–squamous cell
Pneumonectomies
Complete Lymph Node Dissection
Postoperative RT
Receiving Planned RT
Median Follow-up Time
59 Years
36%
25%
39%
46%
54%
35%
70.4%
59 Years
37%
24%
39%
47%
53%
35%
84.2%
Characteristics Chemotherapy
(n = 932)
Control
(n = 935)
IALT22
61 Years
39%
31%
29%
51%
49%
24%
55%
43%
74%
61 Years
38%
34%
28%
49%
51%
26%
53%
43%
89%
Chemotherapy
(n = 472)
Control
(n = 465)
ALPI23*
Patient Characteristics of the IALT and ALPI Studies22,23Table 2
*From the final analysis, 108 patients from one center were excluded (54 in each arm) because of serious concerns about data integrity. 
Not Reported
30%
56 Months 56 Months
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The CALGB 9633 study accrued patients
very slowly and, based on occurrence of events
over time, the requested number of patients was
amended to 384. It was well balanced for known
prognostic factors between the treatment and
control arms. An independent data monitoring
committee stopped the study early at a planned
interim analysis after the inclusion of 344 pa-
tients based on unequivocal superiority of one
arm over the other. 
The CALGB 9633 study demonstrates a re-
markable improvement in OS compared with the
no-treatment group (12% at 4 years). However, it
should be known that the median follow-up is
only 34 months, and there is still a huge number
of censored patients on both survival curves. The
magnitude of benefit of the use of adjuvant car-
boplatin/paclitaxel was substantially greater than
one might have predicted on the basis of IALT
and the metaanalysis, and, considering the avail-
able data, an overestimation of the treatment ef-
fect appears reasonable.
Most notably, the delivery of chemotherapy was excellent in
the treatment group, nearly 85% of patients in the treatment
group received 4 cycles of chemotherapy. Toxicity in this group
of patients was minimal, with only 36% of patients having
grade 3/4 myelosuppression. There were no treatment-related
deaths, which is an important aspect of an adjuvant study. Dose
delays were uncommon, attesting to the well tolerated nature of
the chemotherapy.25
It could be argued that the positive results were caused by a
uniform patient population, a regimen that was well tolerated
and nontoxic, and the fact that such a high fraction of patients
was able to complete all the planned cycles of chemotherapy.
The NCIC-BR.10 study randomized 482 patients with com-
pletely resected stage IB/II NSCLC to observation or 4 cycles of
cisplatin/vinorelbine (Table 3). Cisplatin was given on days 1
and 8, which allowed for better dose intensity. Overall survival
was significantly improved (5-year survival, 69% vs. 54%; HR,
0.69; P = 0.01) as well as PFS. 
This regimen was less well tolerated than in the CALGB
study, with the occurrence of grade 3/4 neutropenia in 73% of
the patients and febrile neutropenia in 6%. Thirty-four percent
of patients did not begin therapy or received only 1 cycle, and
adjuvant treatment was terminated early for patient refusal in
30% of the cases and drug toxicity in 12% of patients.26 All to-
gether, these toxicity issues partially limit the applicability of
such treatment in the daily practice.
Why were these 2 studies largely positive, exceeding so far the
5% benefit hypothesized by the metaanalysis and confirmed by
the IALT study? Several potential confounding factors should be
taken into consideration. First, each adjuvant study enrolled a
select patient population (Table 4)22,23,25,26; therefore, it is not
known how much is representative of the entire population of
patients with completely resected NSCLC. Second, in many of
these studies no information is available about the proportion of
patients who, during surgical resection, underwent systematic
lymph nodal dissection or mediastinal lymph node sampling. In
a recent randomized clinical study, systematic lymph nodal dis-
section was found to significantly influence survival in every
stage of resectable NSCLC.32 Third, patients with lung cancer
frequently have comorbidities, including chronic obstructive
pulmonary disease and cardiovascular diseases, that were found
to significantly affect survival.33,34 Additionally, an imbalance in
the proportion of patients who potentially quit smoking after
radical surgery may account for survival differences. This is
shown in a study of 273 patients with pathologic stage I
NSCLC in which the amount of smoking exposure was found
to be a highly significant predictor of OS.35
Uracil/Tegafur–Based Trials and Metaanalysis 
Several Japanese trials have evaluated the potential of oral flu-
orouracil derivatives as adjuvant treatments alone or in combina-
tion with other agents. Initially, 2 Japanese trials investigated the
prolonged administration (6 months to 1 year) of uracil/tegafur
(UFT; molar ratio of 1:4). Both trials considered eligible patients
with completely resected NSCLC of stages I-III and showed a
survival advantage for patients treated with UFT. In one study,
patients were randomized to cisplatin, doxorubicin followed by
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Male Sex
PS of 0
Squamous Histology
Stage IB Disease
Stage II (A/B) Disease
Survival
  Progression-free
  Overall
Median Follow-up Time
63%
58%
38%
100%
0
4-Year
50%
59%
65%
55%
39%
100%
0
4-Year
61%‡
71%||
Characteristic
or Outcome Observation
(n = 171)
Treatment*
(n = 173)
CALGB 963325
64%
49%
38%
45%
55%
5-Year
48%
54%
66%
49%
37%
46%
54%
5-Year
61%§
69%¶
Observation
(n = 239)
Treatment†
(n = 243)
NCIC BR.1026
Patient Characteristics and Main Efficacy Outcomes of the CALGB 9633
and NCIC BR.10 Studies25,26
Table 3
*Treatment consisted of carboplatin/paclitaxel. 
†Treatment consisted of cisplatin/vinorelbine. 
‡P = 0.035.
§P = 0.012.
||P = 0.028. 
¶P = 0.002. 
34 Months Not available
IALT22
ALPI23
CALGB 963325
NCIC BR.1026
1995-2000
1994-1999
1996-2003
1995-2000
1867
1209
344
482
339
242
49
80
Study EnrollmentPeriod
Enrolled
Patients
Enrolled Patients
per Year
Patient Enrollment of Randomized Studies of Adjuvant 
Chemotherapy22,23,25,26
Table 4
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UFT, or observation; whereas in the other study, patients were
randomly allocated to receive 1 cycle of cisplatin/vindesine fol-
lowed by oral UFT for 1 year, oral UFT alone, or observa-
tion.36,37 In the first trial, survival advantage was shown only
after adjustment in the imbalance for major prognostic factors,
whereas in the second, postoperative chemotherapy was found to
be a significant prognostic factor for survival. The overall 5-year
survival rates were 64.1% for the UFT group (n = 103) and 49%
for the surgery-alone group (n = 98; P = 0.02).
A clinical study limited to 225 patients with stage I/II
NSCLC reported on oral UFT with MVP as adjuvant
chemotherapy. The 5-year survival rates were 71.1% for the sur-
gery-alone group and 76.8% for the chemotherapy group, with
no significant difference observed. A subset analysis showed
prognostic advantage for the chemotherapy group.38 Another
study randomized 221 patients with resected stage I/II NSCLC
to UFT alone or control and failed to show any improvement in
5-year survival rate (79% vs. 75%).39 At the beginning of 2004,
a large confirmatory phase III trial of adjuvant UFT for 2 years
versus control in resected stage I adenocarcinoma of the lung was
reported. Stratification was based on age, sex, and pathologic
stage (T1 vs. T2). Final results at 5 years showed a modest but
significant OS benefit (P = 0.035) that was essentially confined
to patients with T2 disease (P = 0.051).40 One questionable
point in this trial is the absence of any advantage in disease-free
survival (DFS) for the UFT-treated arm, which clearly contrasts
with all the positive platinum agent–based adjuvant studies
(IALT,22 NCIC BR.10,25 CALGB 963326) in which improve-
ment in OS for patients receiving adjuvant chemotherapy was
invariably associated with a similar or greater magnitude of im-
provement in DFS. 
Most of the previously mentioned trials have been included in a
specific metaanalysis evaluating the efficacy of UFT alone, includ-
ing 2003 patients globally, 90% with stage I NSCLC. Patients
treated with UFT had improvements in 5-year survival of 4.6%
(HR, 0.77; 95% CI, 0.63-0.94; P = 0.01) and 7-year survival of
7% (HR, 0.74; 95% CI, 0.61-0.88; P = 0.001).41
In most of these UFT studies, adjuvant treatment was
planned for 2 consecutive years, and treatment compliance was
generally higher than that observed in cisplatin-based studies.
The concept of relatively mild, low-dose continuous adjuvant
therapy is attractive, but the absence of confirmatory adjuvant
UFT studies outside Japan strongly limit the applicability of
these data into clinical practice because, even recently, random-
ized studies in second-line treatment for NSCLC with gefitinib,
an epidermal growth factor receptor (EGFR) tyrosine kinase
(TK) inhibitor, indicated a different activity of the drug when
tested among Japanese and non-Japanese patients.42,43
Molecularly Targeted Agents in the Adjuvant Setting
There is a good rationale for the use of molecularly targeted
therapies in early NSCLC, considering that many of the path-
ways these agents target have been shown to be altered in very
early phases in the natural history of the disease.44 The small-
molecule TK inhibitor gefitinib inhibits EGFR, believed to pro-
mote tumor cell growth and metastases. A phase III randomized
trial will test the effectiveness of gefitinib in the adjuvant setting
for patients with curatively resected stage IB, II, or IIIA disease.
The trial will compare OS for patients treated with daily gefi-
tinib or placebo. Treatment in both arms will continue for 2
years in the absence of disease progression or unacceptable tox-
icity. The projected accrual is 1242 patients (621 per treatment
arm), with patients stratified according to disease stage (stage IB
vs. II vs. IIIA) and histologic subtype (squamous cell vs. other
types). After publication of the IALT study of adjuvant cytotox-
ic chemotherapy, cisplatin-based therapy was considered a ther-
apeutic option before the randomization of the patients, and it
is now considered a stratification factor. The trial will also de-
termine the prognostic significance of the EGFR expression
level, phosphorylation, and mutations in the primary tumor.
Molecular Prognostic Factors 
In 30% of lung adenocarcinomas and in approximately 10%
of large-cell carcinomas, the K-ras gene was found to be muta-
tionally activated, and in pivotal studies this feature was a prog-
nostic determinant of survival, regardless of the stage of disease.45
These data have not been fully confirmed by additional clinical
studies.46 The genetic alterations affecting the p53 gene are
among the most common changes that occur during malignant
progression of several types of tumors, including NSCLC. How-
ever, studies that explored the prognostic role of p53 mutations
in NSCLC reported highly conflicting results and no definitive
information could be obtained from those studies.47
The expression of K-ras, p53, and Ki-67 was prospectively
evaluated in subgroups of patients included in the ALPI trial;
unfortunately, no relevant prognostic implication was found.23
The CALGB 8633 study also aimed at evaluating the prevalence
of 10 molecular biologic markers (growth factors HER2/neu
and K-ras codon 12 mutations, cell-cycle factors Ki-67 and
retinoblastoma, apoptosis factors p53 and bcl-2, angiogenesis
factor VIII, and adhesion protein CD44, and motility factor
gelsolin) to determine the influence of adjuvant chemotherapy
on cancer-free survival relative to marker expression in these pa-
tients, but this information is not yet available.30 However, it
should be noted that the largest biomarker study, retrospective-
ly performed in 515 cases of resected stage I NSCLC, failed to
show any significant association between survival and the ex-
pression of an extensive panel of biomarkers, including EGFR,
HER2/neu, bcl-2, p53, and angiogenesis.48
Neoadjuvant Studies in Early-Stage NSCLC
The benefits of neoadjuvant chemotherapy have already been
widely accepted in the setting of locally advanced marginally re-
sectable (stage IIIA N2) and unresectable disease (stage IIIB). A
pivotal phase III study of a French thoracic cooperative group
compared the administration of 2 courses of mitomycin C/ifos-
famide/cisplatin followed by surgery compared with surgery
alone in resectable stages I-IIIA disease. Responding patients re-
ceived additional chemotherapy after surgery. The response rate
to induction therapy was 64% (11% pathologic complete re-
sponse). A survival advantage, potentially delayed for high peri-
operative toxicity, was observed in the combined arm. Median
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survival time favored the combined approach (36 months vs. 26
months; P = 0.11, log-rank test). After 150 days, the effect of pe-
rioperative chemotherapy on survival was significantly favorable
(relative risk, 0.71; P = 0.03). A quantitative interaction between
nodal stage and treatment was also noted, with the benefit from
perioperative chemotherapy confined to patients with N0/1 dis-
ease (P = 0.008). Disease-free survival was significantly longer in
the perioperative chemotherapy arm (P = 0.02), with a similar
interaction in patients with N0/1 disease (P = 0.002). Risk of
distant metastasis was significantly decreased in the group treat-
ed with preoperative chemotherapy (HR, 0.54; P = 0.01).49
Recently, several other neoadjuvant chemotherapy trials in
the setting of resectable disease (Table 5) have been initiated.
Unfortunately, the accrual of patients in these studies is slow
and may further be compromised by the fact that a surgery-
alone arm is considered unethical based on the results of the re-
cently concluded adjuvant studies.
The Southwest Oncology Group (SWOG) S9900 trial was
planned to assess whether preoperative chemotherapy with pacli-
taxel/carboplatin improves survival compared with surgery alone
in previously untreated patients with stage IB, II, or selected stage
IIIA (T3 N1) NSCLC. Operative mortality, response, and safety
are evaluated. Samples will also be evaluated for molecular biolog-
ic factors and any correlation with outcome. Patients have been
stratified on the basis of disease stage (IB/IIA vs. IIB/IIIA). The
planned number of patients was set at 600, but the trial closed on
July 15, 2004, because of the previously described studies showing
the efficacy of adjuvant chemotherapy in this patient population,
making continued accrual to the control arm inappropriate.
Similar to the SWOG 9900, the Chemotherapy in Early Stages
Trial (ChEST) evaluates the role of preoperative chemotherapy in
patients with resectable stage IB, II, and selected IIIA (T3 N1)
NSCLC, but the chemotherapy evaluated consists of gemcitabine
1000 mg/m2 on days 1 and 8 and cisplatin 75 mg/m2 on day 2.
Patients are randomized to immediate surgery followed by obser-
vation or induction gemcitabine/cisplatin for 3 cycles followed by
surgery. Patient accrual was set at 700 and currently > 250 pa-
tients are entered in the study. The primary endpoint is OS.
The Neoadjuvant Taxol® Carboplatin Hope (NATCH) trial
compares the benefit of preoperative versus postoperative
chemotherapy with paclitaxel/carboplatin versus surgery alone
in stage IA (> 2.5 cm), IB, II, and IIIA (T3 N1) NSCLC.
Planned accrual was set at > 600 patients. Paclitaxel 200 mg/m2
over 3 hours and carboplatin at an area under the curve of 6 are
administered before surgery (arm 1) or after surgery (arm 3; Fig-
ure 1). Genetic polymorphisms for the xeroderma pigmentosum
D gene at codons 751 and 312 were also evaluated for a corre-
lation with response to treatment. Preliminary data about this
trial are awaited in 2005.
Finally, a new French trial is currently evaluating the efficacy
of 2 different regimens (cisplatin/gemcitabine and carbo-
platin/paclitaxel) and 2 different schedules (2 vs. 4 cycles of pre-
operative chemotherapy) in patients with stage I/II NSCLC.
The expected number of patients is 130 in each arm for a total
number of 520 patients. The primary endpoint is OS. 
Conclusion
The most recent randomized studies of adjuvant chemother-
apy testing the efficacy of the newer generation of cytotoxic
agents in combination with platinum compounds have sug-
gested a positive impact on efficacy outcomes (DFS and OS).
A precise estimation of the survival gain that a metaanalysis es-
timated to be approximately 5% at 5 years needs to be fine-
tuned. Two randomized clinical studies performed in highly
selected patient populations support the use of adjuvant treat-
ment in completely resected stage IB/II NSCLC. Two addi-
tional larger randomized clinical studies (one marginally
positive and one marginally negative) in all stages of complete-
ly resected NSCLC indicate that, if any benefit from adjuvant
chemotherapy exists, it is approximately 5% at 5 years. Anoth-
er metaanalysis that will review the most recent generation of
these positive and negative randomized clinical studies per-
formed in the past 10 years will greatly contribute to assess
more precisely the role of adjuvant chemotherapy. 
Despite these encouraging results, reliable predictive and
prognostic factors represent a priority to avoid the exposure of
most patients to unnecessary treatments. In this perspective,
genomics (or pharmacogenomics) and proteomics may in the
near future drive the detection of those patients who are ideal
candidates for adjuvant treatments. Although molecular-target-
Giorgio V. Scagliotti, Silvia Novello
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*The study was halted in July 2004 after the presentation of the data of the CALGB 9633 and 
NCIC BR.10 trials showing the positive impact of adjuvant chemotherapy.25,26
Abbreviations: IFCT = Intergroupe Francophone de Cancérologie Thoracique; MRC = Medical 
Research Council
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ed therapies appear in the adjuvant setting as a rationally de-
signed approach, clinical validation of these “proof of princi-
ple” concepts through carefully designed clinical trials is
absolutely mandatory.
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